Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. - Wikidata - wikimedia - TriplyDB

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

http://www.wikidata.org/entity/Q37173102

about

Lymphangioleiomyomatosis: differential diagnosis and optimal management Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.Diffuse Cystic Lung Disease. Part I.Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer.A case of lymphangioleiomyomatosis associated with endometrial cancer and severe systemic lupus erythematosus.Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis Airway smooth muscle in airway reactivity and remodeling: what have we learned?Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2 Metabolic Impact of Rapamycin (Sirolimus) and B-Estradiol Using Mouse Embryonic Fibroblasts as a Model for Lymphangioleiomyomatosis.Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.

P2860

Q27022412-BF295790-726D-47BF-AF27-FA0DAF9AAFDF Q33720145-E9C3E637-1238-4916-8994-27DC14E5073F Q33722950-E2472AF9-9BE1-458D-9428-A01DCB65C8F1 Q34204852-06A2D8C1-243E-40B8-8F22-2FC3CCDB5656 Q34569989-1D54C134-3657-4AAE-B4A6-F2CE21990C50 Q35074335-6520FC23-BF75-49A3-80D9-C9F355AE55EA Q35154337-1C27D979-0E5E-4FCB-BFB3-E349DC8C6F8E Q36067790-53C23338-B9D9-48A0-8235-7C7BFBC4DC74 Q37193373-86CFA903-C7EC-41F6-BC48-6FB7CA13268D Q37397803-A6216639-AD2C-40F6-9777-C8AF5E0FF4D9 Q37417526-84C731EE-35FF-4154-A5B1-BE874417AC78 Q37440525-13C45290-B904-44DF-B4E1-7C32E897CF4A Q37641575-C39F5855-42E7-4961-A4C6-127F626592E1 Q38675393-88E1EA43-C210-44F7-BEC6-27A7EEADB399 Q38895095-046AE310-D491-4468-BAFA-EFE0AF2043C9 Q42595723-679EA62C-EF64-4B3F-9397-BE367F557A3A

P2860

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

http://www.wikidata.org/entity/Q37173102

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

@en

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

@nl

type

label

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

@en

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

@nl

prefLabel

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

@en

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

@nl

P1433

Q37173102-42DA49BB-F5B8-4EAF-B43E-6855E4CCD13A

P1476

Q37173102-FA9A9690-45C4-472B-BF17-BC7E656DBAA8

P2093

Q37173102-24BC2353-4185-475B-9678-04CB232CA34F

Q37173102-78A7F8CB-8332-4CB7-8819-92AE81F3CA6F

Q37173102-8F666B22-63F3-4D45-B1E5-668109B29D92

Q37173102-A0CD7C66-4F81-4637-8F70-6BE61F675E61

Q37173102-AA6ADD6F-6986-4008-B10E-C1C0E28E7329

Q37173102-DAF95C09-2119-4C44-A05A-2F3434FB6818

P2860

Q37173102-11AA8774-E8B0-4976-99D2-FDDD2FF7C478

Q37173102-18376F4E-B34A-4BE0-B4AA-44BFE871B394

Q37173102-23106467-BFDC-48B0-B8EA-17D3FA84FAE2

Q37173102-2D42AD55-893F-406E-A8BB-8A3F7A391297

Q37173102-4732C66E-1288-4E09-8157-CDC46AF1AB50

Q37173102-4D3044FC-EF8A-4D35-B1A4-2455BA2E41A5

Q37173102-4D634BB2-83A2-4A0B-83E2-6ADBE8AA564D

Q37173102-4E4DD1B1-AC2D-492A-A258-36952396E157

Q37173102-55143BDB-C028-4B1F-85D1-F1BC93B976D9

Q37173102-608E4B9D-1322-484A-AF82-109294D3C7A5

P304

Q37173102-60BF3B88-09FE-4038-A5D5-CC5CEDDFDD86

P31

Q37173102-680798D5-7E14-465F-A21E-0785AFD9624F

P356

Q37173102-3D47D268-4E6D-4531-87F7-B9089859D504

P407

Q37173102-AC0B9ADA-5B97-46DC-9395-1A842C5F6AD4

P433

Q37173102-53168066-6BEF-45CC-8138-8BEC62B57B5A

P478

Q37173102-7A20C1D3-08EB-4FA4-98F2-07622FFF4637

P577

Q37173102-B077A642-15A3-462F-AD83-62C2601D49B0

P5875

Q37173102-8E3CD1F2-E817-4A3B-8265-832121FB75F0

P698

Q37173102-EEDB1930-D4E1-4173-A45B-FEB7765409D2

P921

Q37173102-F8EC506F-DBCE-4ADB-9D23-1D411FC48834

P932

Q37173102-1C81FEAF-58E0-4D20-861E-EEE9F4AE310E

P356

PNAS.1309110110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.

@en

P2093

Didem Ilter

http://www.w3.org/2001/XMLSchema#string

Elizabeth Petri Henske

http://www.w3.org/2001/XMLSchema#string

Jane J Yu

http://www.w3.org/2001/XMLSchema#string

John Blenis

http://www.w3.org/2001/XMLSchema#string

Nickolas Blenis

http://www.w3.org/2001/XMLSchema#string

Xiaoxiao Gu

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis

Molecular mechanisms of mTOR-mediated translational control

The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.

ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events.

Graded mitogen-activated protein kinase activity precedes switch-like c-Fos induction in mammalian cells.

Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

P304

14960-14965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1309110110

http://www.w3.org/2001/XMLSchema#string

P407

P433

37

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256189945

http://www.w3.org/2001/XMLSchema#string

P698

23983265

http://www.w3.org/2001/XMLSchema#string

P921

P932

3773757

http://www.w3.org/2001/XMLSchema#string